NTT-COMMUNICATIONS
8.4.2021 04:02:11 CEST | Business Wire | Press release
NTT Communications Corporation (NTT Com), the ICT solutions and international communications business within the NTT Group, announced today that it has succeeded in a trial sharing of production-line data related to CO2 emissions via a prototype platform that enables interconnection via IDS standards which support data sovereignty in GAIA-X data ecosystem. The trial data, which normally would not be available for sharing due to its high confidentiality even though partners engaged in actual business would need to perform CO2 emissions calculations, was transmitted securely to designated sites in Germany and Japan from Switzerland Innovation Park Biel/Bienne in Switzerland.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210407006040/en/
GAIA-X is an initiative announced by the German and French governments in October 2019 to support data sharing via infrastructure that ensures data protection, transparency, reliability and interoperability to protect the rights of European companies, governments, institutions and citizens.
NTT Com conducted the trial under the assumption that such data will be used by companies engaged in actual business to review their manufacturing methods to achieve greater decarbonization. The prototype platform, which enables interconnection with IDS Connectors, also is equipped with DATA Trust® , a mechanism for the secure sharing of highly confidential data.
The trial involved the sharing of electricity-consumption data that business partners typically would use to calculate CO2 emissions generated during the manufacturing of specific products. The trial confirmed that NTT’s platform can share such data securely with only those parties permitted by law or contract.
The prototype was developed using Nippon Telegraph and Telephone Corporation (Software Innovation Center)'s business-to-business data distribution technology, in cooperation with Robot Revolution & Industrial IoT Initiative (RRI), International Data Spaces Association (IDSA), Fraunhofer-Gesellschaft, Switzerland Innovation Park Biel/Bienne and Japan Innovation Park.
NTT Com plans to exhibit the trial results at the joint booth of IDSA and RRI during the Hannover Messe industrial fair in Germany from April 12-16.
“Japan is very close to Europe in the field of industry, with a strong experience in automotive, steel, or manufacturing,” said Hubert Tardieu, Chairman of GAIA-X AISBL. “The main objective in every industry is nowadays data sharing and service orchestration like in GAIA-X. NTT Communications starts with a first run in data sharing between, Japan, Germany and Switzerland, using the IDS standard which supports data sovereignty in GAIA-X data ecosystems. We are proud at GAIA-X AISBL to strongly support the launching of the japan Hub trough NTT Communications and start more use cases around GAIA-X.”
Going forward, NTT Com will build a test environment in Japan to connect with GAIA-X and start interoperability tests with multiple partner companies around the world this summer. If all goes well, NTT Com hopes to launch an official platform within the fiscal year ending in March 2022. The launch would be coordinated with organizations and groups involved with international data distribution, including Data Society Alliance, OPC Foundation Japan, RRI, GAIA-X AISBL and IDSA.
Data utilization has become indispensable for initiatives such as global decarbonization, the early achievement of the United Nations’ Sustainable Development Goals and the strengthening of industries. At the same time, however, legal systems and technologies to regulate and manage data use are being developed around the world, one of which is GAIA-X, to prevent the leakage of corporate and national secrets and to protect data sovereignty.
In the future, it is expected that companies will be required to use GAIA-X to send and receive highly confidential data to and from business partners in European countries. This means that companies unable to use GAIA-X would not be able to do business with European partners if sensitive data sharing were involved. NTT Com’s envisioned platform, however, would enable such companies to easily connect to GAIA-X without have to spend valuable time and money on an acceptable data-sharing solution.
About NTT Communications
NTT Communications solves the world's technology challenges by helping enterprises overcome complexity and risk in their ICT environments with managed IT infrastructure solutions. These solutions are backed by our worldwide infrastructure, including industry leading, global tier-1 public and private networks reaching over 190 countries/regions, and more than 500,000m2
of the world's most advanced data center facilities. Our global professional services teams provide consultation and architecture for the resiliency and security required for your business success, and our scale and global capabilities in technology world are unsurpassed. Combined with NTT Ltd., NTT Data, and NTT DOCOMO, we are NTT Group.
www.ntt.com
| Twitter@NTT Com | Facebook@NTT Com | LinkedIn@NTT Com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210407006040/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom